This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aceragen 배당금

배당금 기준 확인 0/6

Aceragen does not have a record of paying a dividend.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$4.88
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: Insufficient data to determine if ACGN's dividends per share have been stable in the past.

배당금 증가: Insufficient data to determine if ACGN's dividend payments have been increasing.

시장 대비 배당 수익률

Aceragen 시장 대비 배당 수익률

ACGN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ACGN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (ACGN)	n/a

주목할만한 배당금: Unable to evaluate ACGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

고배당: Unable to evaluate ACGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

주주에 대한 수익 배당금

수익 보장: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

주주에 대한 현금 배당금

현금 흐름 범위: Unable to calculate sustainability of dividends as ACGN has not reported any payouts.

This company listing is no longer active

Aceragen 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Price target decreased by 88% to US$17.00

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals completes acquisition of Aceragen

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought US$60k worth of stock

Independent Chairman recently bought US$101k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Price target increased to US$8.60

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

New 90-day high: US$5.40

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

President recently sold US$161k worth of stock

President notifies of intention to sell stock

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

New 90-day high: US$3.33

Idera Pharmaceuticals, Inc. Announces Board Changes

Idera Pharma names new operations chief

Earnings beat expectations

Idera Pharmaceuticals EPS misses by $0.37

New 90-day high: US$2.69

New 90-day high: US$2.68

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

New 90-day high - US$2.22

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기